These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 26659915)

  • 1. Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma.
    Cartron G; Hourcade-Potelleret F; Morschhauser F; Salles G; Wenger M; Truppel-Hartmann A; Carlile DJ
    Haematologica; 2016 Feb; 101(2):226-34. PubMed ID: 26659915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.
    Sehn LH; Goy A; Offner FC; Martinelli G; Caballero MD; Gadeberg O; Baetz T; Zelenetz AD; Gaidano G; Fayad LE; Buckstein R; Friedberg JW; Crump M; Jaksic B; Zinzani PL; Padmanabhan Iyer S; Sahin D; Chai A; Fingerle-Rowson G; Press OW
    J Clin Oncol; 2015 Oct; 33(30):3467-74. PubMed ID: 26282650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study.
    Morschhauser FA; Cartron G; Thieblemont C; Solal-Céligny P; Haioun C; Bouabdallah R; Feugier P; Bouabdallah K; Asikanius E; Lei G; Wenger M; Wassner-Fritsch E; Salles GA
    J Clin Oncol; 2013 Aug; 31(23):2912-9. PubMed ID: 23835718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.
    Gibiansky E; Gibiansky L; Buchheit V; Frey N; Brewster M; Fingerle-Rowson G; Jamois C
    Br J Clin Pharmacol; 2019 Sep; 85(9):1935-1945. PubMed ID: 31050355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study.
    Salles GA; Morschhauser F; Solal-Céligny P; Thieblemont C; Lamy T; Tilly H; Gyan E; Lei G; Wenger M; Wassner-Fritsch E; Cartron G
    J Clin Oncol; 2013 Aug; 31(23):2920-6. PubMed ID: 23835715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
    Ogura M; Tobinai K; Hatake K; Uchida T; Suzuki T; Kobayashi Y; Mori M; Terui Y; Yokoyama M; Hotta T
    Cancer Sci; 2013 Jan; 104(1):105-10. PubMed ID: 23046388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
    Morschhauser F; Le Gouill S; Feugier P; Bailly S; Nicolas-Virelizier E; Bijou F; Salles GA; Tilly H; Fruchart C; Van Eygen K; Snauwaert S; Bonnet C; Haioun C; Thieblemont C; Bouabdallah R; Wu KL; Canioni D; Meignin V; Cartron G; Houot R
    Lancet Haematol; 2019 Aug; 6(8):e429-e437. PubMed ID: 31296423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.
    Michot JM; Bouabdallah R; Vitolo U; Doorduijn JK; Salles G; Chiappella A; Zinzani PL; Bijou F; Kersten MJ; Sarmiento R; Mosulen S; Mendez C; Uttamsingh S; Pourdehnad M; Hege K; Chen T; Klein C; Hagner PR; Nikolova Z; Ribrag V
    Lancet Haematol; 2020 Sep; 7(9):e649-e659. PubMed ID: 32758434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obinutuzumab for the treatment of chronic lymphocytic leukemia.
    Rogers KA; Jones JA
    Drugs Today (Barc); 2014 Jun; 50(6):407-19. PubMed ID: 24983589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients.
    Salles G; Morschhauser F; Lamy T; Milpied N; Thieblemont C; Tilly H; Bieska G; Asikanius E; Carlile D; Birkett J; Pisa P; Cartron G
    Blood; 2012 May; 119(22):5126-32. PubMed ID: 22431570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma.
    Herting F; Friess T; Bader S; Muth G; Hölzlwimmer G; Rieder N; Umana P; Klein C
    Leuk Lymphoma; 2014 Sep; 55(9):2151-5160. PubMed ID: 24304419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.
    Tobinai K; Klein C; Oya N; Fingerle-Rowson G
    Adv Ther; 2017 Feb; 34(2):324-356. PubMed ID: 28004361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies.
    Sehn LH; Assouline SE; Stewart DA; Mangel J; Gascoyne RD; Fine G; Frances-Lasserre S; Carlile DJ; Crump M
    Blood; 2012 May; 119(22):5118-25. PubMed ID: 22438256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obinutuzumab for chronic lymphocytic leukemia.
    Rioufol C; Salles G
    Expert Rev Hematol; 2014 Oct; 7(5):533-43. PubMed ID: 25163491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388).
    Herting F; Herter S; Friess T; Muth G; Bacac M; Sulcova J; Umana P; Dangl M; Klein C
    Eur J Haematol; 2016 Nov; 97(5):461-470. PubMed ID: 26993060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
    Goede V; Fischer K; Busch R; Engelke A; Eichhorst B; Wendtner CM; Chagorova T; de la Serna J; Dilhuydy MS; Illmer T; Opat S; Owen CJ; Samoylova O; Kreuzer KA; Stilgenbauer S; Döhner H; Langerak AW; Ritgen M; Kneba M; Asikanius E; Humphrey K; Wenger M; Hallek M
    N Engl J Med; 2014 Mar; 370(12):1101-10. PubMed ID: 24401022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.
    Grigg A; Dyer MJ; Díaz MG; Dreyling M; Rule S; Lei G; Knapp A; Wassner-Fritsch E; Marlton P
    Haematologica; 2017 Apr; 102(4):765-772. PubMed ID: 28011903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma.
    Bender B; Li CC; Marchand M; Turner DC; Li F; Vadhavkar S; Wang B; Deng R; Lu J; Jin J; Li C; Yin S; Wei M; Chanu P
    Clin Transl Sci; 2024 Jun; 17(6):e13825. PubMed ID: 38808543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations.
    Reda G; Orofino N; Cassin R; Sciumè M; Fattizzo B; Cortelezzi A
    Expert Opin Drug Saf; 2016 Jun; 15(6):865-73. PubMed ID: 26967902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody.
    Goede V; Klein C; Stilgenbauer S
    Oncol Res Treat; 2015; 38(4):185-92. PubMed ID: 25877943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.